SCHEMBL3020118

SCHEMBL3020118

COc1ccc(S(=O)(=O)N2CCN(c3nc(Cc4cc(F)cc(F)c4)cs3)CC2)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
RECQL P46063 2/20 0.48
USP2 O75604 2/20 0.48
HSD17B10 Q99714 1/20 0.48
LMNA P02545 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
TP53 P04637 1/20 0.43
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 3/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 1/20 0.39
PKM P14618 1/20 0.39
CCR3 P51677 2/20 0.39
CCR5 P51681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008292 0.94 MAPT (0.45) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3013251 0.93 ALDH1A1 (0.52) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3002759 0.92 MAPT (0.45) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3001778 0.91 MAPT (0.46) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3007417 0.90 MAPT (0.46) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3015059 0.90 MAPT (0.43) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3013096 0.90 MAPT (0.45) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3015949 0.89 MAPT (0.43) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3654780 0.89 MAPT (0.41) MAPTRECQLUSP2HSD17B10LMNA
SCHEMBL3015761 0.89 ALDH1A1 (0.47) MAPTRECQLUSP2HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885RECQL 1564/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.